Helsinn announces publication of latest mechlorethamine gel research, highlighting its efficacy and safety

18 February 2021

Il rebus vaccini, tra ritardi e polemiche sui brevetti – Intervista a Giorgio Calderari, Presidente FIT

15 February 2021

Pharma Boardroom – Interview to Giorgio Calderari – Chairman, Farma Industria Ticino (FIT)

15 February 2021

Modem RSI Rete 1 – Covid: la corsa ai vaccini, intervista al Presidente FIT Giorgio Calderari

4 February 2021

Perché i vaccini sono in ritardo? Intervista a Giorgio Calderari, Presidente di FIT

3 February 2021

Tamponi a tappeto per i lavoratori? Intervista a Giorgio Calderari, Presidente di FIT e Group General Manager di Helsinn

26 January 2021

Helsinn Announces First Patient Dosed in Phase 1/2 Study of TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities

12 January 2021

Helsinn Demonstrates Commitment to raising Awareness on Cachexia by Supporting Cachexia Societies Conferences

10 December 2020

Helsinn to present two posters at the San Antonio Breast Cancer Symposium (SABCS) 2020 evaluating high CINV recurrence in breast cancer patients and CINV duration as its predictor

9 December 2020

Helsinn and Kyowa Kirin Asia Pacific sign exclusive license and distribution agreement to strengthen their presence in Asia Pacific’s rare disease therapy area

1 December 2020